Sirzat Yesilkaya1, Cengizhan Acikel2, Berna Eren Fidanci3, Adem Polat4, Betül Sozeri5, Nuray Aktay Ayaz6, Balahan Bora Makay7, Dogan Simsek4, Nurver Akinci8, Gul Özçelik8, Salih Kavukçu7, Sevinc Emre9, Osman Donmez10, Ali Delibas11, Selcuk Yüksel12, Afig Berdeli5, Hakan Poyrazoglu13, Mehmet Saldir4, Kursat Fidanci4, Nilgun Çakar14, Harun Peru15, Sevcan Bakkaloglu16, Yilmaz Tabel17, Oktay Sari1, Umit Aydogan1, Salim Ozenc1, Gokalp Basbozkurt4, Erbil Unsal7, Özgür Kasapcopur9, Faysal Gok18, Seza Ozen19, Erkan Demirkaya20. 1. Gulhane Military Medical Academy, Department of Family Medicine, Ankara, Turkey. 2. Gulhane Military Medical Faculty, Department of Biostatistics, Ankara, Turkey. 3. Gulhane Military Medical Academy, School of Nursing, Ankara, Turkey, Turkey. 4. Gulhane Military Medical Faculty, Department of Pediatrics, Ankara, Turkey. 5. Ege University Faculty of Medicine, Pediatric Rheumatology, Izmir, Turkey. 6. Kanuni Sultan Suleyman Research and Training Hospital, Pediatric Nephrology-Rheumatology, Istanbul, Turkey. 7. Dokuz Eylul University Hospital, Department of Pediatrics, İzmir, Turkey. 8. Sisli Etfal Education and Research Hospital, Department of Pediatrics, Istanbul, Turkey. 9. Istanbul University, Department of Pediatrics, Istanbul, Turkey. 10. Uludag University Medical Faculty, Dept. of Pediatric Rheumatology, Bursa, Turkey. 11. Akdeniz University, Department of Pediatrics, Mersin, Turkey. 12. Pamukkale University Medical Faculty, Dept. of Paediatrics, Denizli, Turkey. 13. Erciyes University Medical Faculty, Department of Paediatrics, Kayseri, Turkey. 14. Ministry of Health Dıskapı Children's Hospital, Paediatric Nephrology, Ankara, Turkey. 15. Selcuk University, Department of Paediatrics, Ankara, Turkey. 16. Gazi Universty, Department of Paediatrics, Ankara, Turkey. 17. Inonu University, Paediatric Nephrology, Malatya, Turkey. 18. Gulhane Military Medical Faculty, Paediatric Rheumatology Unit, Ankara, Turkey. 19. Hacettepe University, Paediatric Nephrology and Rheumatology Unit, Ankara, Turkey. 20. Gulhane Military Medical Faculty, Paediatric Rheumatology Unit, Ankara; and Gulhane Military Medical Academy, FMF Arthritis Vasculitis and Orphan disease Research in Paediatric Rheumatology, Ankara, Turkey. erkandemirkaya@yahoo.com.
Abstract
OBJECTIVES: To develop and assess the validity and reliability of an adherence scale concerning medical treatment in paediatric FMF patients. METHODS: The Medication Adherence Scale in FMF Patients (MASIF) is a 18-item questionnaire that evaluates adherence to medication in four domains. Validation of the instrument was accomplished in paediatric FMF patients (aged 2-18 years) under medication at least for 6 months. The first step was to build up the scale through qualitative approach (with interviews using semi-structured questions). Validation analyses included assessment of feasibility, face and content validity; construct validity, internal consistency and test-retest reliability. RESULTS: One hundred and fifty patients with FMF were enrolled in the study. The mean age of the patients was 11.11±4.02 years and 48.7% of them were male. The MASIF was found to be feasible and valid for both face and content. It correlated with the Morisky Medication Adherence Scale as a gold standard thereby demonstrating good construct validity (r=0.515, p<0.001). Assessment of content validity identified four subscales. The internal consistency, Cronbach's alpha was 0.728. There was a positive and significant correlation between test and retest scores (r=0.843; p<0.001). Also, a significant correlation between parents' and children's reports (r=0.781, p<0.001). CONCLUSIONS: Based on these results, the use of this scale to assess and follow up the adherence to treatment in paediatric FMF patients under medical treatment is recommended.
OBJECTIVES: To develop and assess the validity and reliability of an adherence scale concerning medical treatment in paediatric FMFpatients. METHODS: The Medication Adherence Scale in FMFPatients (MASIF) is a 18-item questionnaire that evaluates adherence to medication in four domains. Validation of the instrument was accomplished in paediatric FMFpatients (aged 2-18 years) under medication at least for 6 months. The first step was to build up the scale through qualitative approach (with interviews using semi-structured questions). Validation analyses included assessment of feasibility, face and content validity; construct validity, internal consistency and test-retest reliability. RESULTS: One hundred and fifty patients with FMF were enrolled in the study. The mean age of the patients was 11.11±4.02 years and 48.7% of them were male. The MASIF was found to be feasible and valid for both face and content. It correlated with the Morisky Medication Adherence Scale as a gold standard thereby demonstrating good construct validity (r=0.515, p<0.001). Assessment of content validity identified four subscales. The internal consistency, Cronbach's alpha was 0.728. There was a positive and significant correlation between test and retest scores (r=0.843; p<0.001). Also, a significant correlation between parents' and children's reports (r=0.781, p<0.001). CONCLUSIONS: Based on these results, the use of this scale to assess and follow up the adherence to treatment in paediatric FMFpatients under medical treatment is recommended.
Authors: T Kallinich; N Blank; T Braun; E Feist; U Kiltz; U Neudorf; P T Oommen; C Weseloh; H Wittkowski; J Braun Journal: Z Rheumatol Date: 2019-02 Impact factor: 1.372